PGP and in situ carcinoma: For the CIS-resistant ovarian cancer IGROVCDDP cell line characterized by P-gp overexpression, treatment with 0.25 μM elacridar increased sensitivity to multiple P-gp substrates—including DTX, PAC, epirubicin, and vinblastine—while it had no effect on drugs not transported by P-gp such as SN-38, 5-FU, and methotrexate [64].